Empirical evidence has demonstrated that the Src inhibitor dasatinib exacerbates colitis by elevating TNF‐α levels, which occurs through the suppression of IL‐10, possibly involving the activation of the Src‐Akt signaling pathway to facilitate IL‐10 production (Hu et al. 2016). Here, AKT1 is linked to colitis.